$135 Million is the total value of VHCP Management, LLC's 17 reported holdings in Q2 2013. The portfolio turnover from Q1 2013 to Q2 2013 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NBIX | New | Neurocrine Biosciences Inc | $26,287,000 | – | 1,964,673 | +100.0% | 19.52% | – |
| IRWD | New | Ironwood Pharmaceuticals Inc | $17,874,000 | – | 1,800,000 | +100.0% | 13.27% | – |
| KERX | New | Keryx Biopharmaceuticals Inc | $15,304,000 | – | 2,048,773 | +100.0% | 11.37% | – |
| DYAX | New | Dyax Corp | $14,382,000 | – | 4,156,508 | +100.0% | 10.68% | – |
| ANAC | New | Anacor Pharmaceuticals Inc | $9,005,000 | – | 1,610,856 | +100.0% | 6.69% | – |
| TSRO | New | TESARO Inc | $8,549,000 | – | 261,130 | +100.0% | 6.35% | – |
| GWPH | New | GW Pharmaceuticals | $7,381,000 | – | 837,800 | +100.0% | 5.48% | – |
| VNDA | New | Vanda Pharmaceuticals Inc | $6,363,000 | – | 787,459 | +100.0% | 4.72% | – |
| BIOD | New | Biodel Inc | $6,046,000 | – | 1,446,413 | +100.0% | 4.49% | – |
| CHTP | New | Chelsea Therapeutics International Ltd | $5,789,000 | – | 2,516,870 | +100.0% | 4.30% | – |
| HPTX | New | Hyperion Therapeutics Inc | $5,610,000 | – | 255,000 | +100.0% | 4.17% | – |
| THLD | New | Threshold Pharmaceuticals Inc | $3,598,000 | – | 684,000 | +100.0% | 2.67% | – |
| GTXI | New | GTx Inc | $3,300,000 | – | 500,000 | +100.0% | 2.45% | – |
| ALXA | New | Alexza Pharmaceuticals Inc | $1,736,000 | – | 399,999 | +100.0% | 1.29% | – |
| BCRX | New | BioCryst Pharmaceuticals Inc | $1,571,000 | – | 1,013,442 | +100.0% | 1.17% | – |
| STML | New | Stemline Therapeutics Inc | $1,192,000 | – | 50,000 | +100.0% | 0.88% | – |
| ANTH | New | Anthera Pharmaceuticals Inc | $666,000 | – | 1,437,623 | +100.0% | 0.50% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2013-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| DBV Technologies | 14 | Q4 2016 | 33.5% |
| BioCryst Pharmaceuticals Inc | 13 | Q4 2016 | 11.9% |
| Ocera Therapeutics | 13 | Q4 2016 | 4.9% |
| Anacor Pharmaceuticals Inc | 12 | Q1 2016 | 35.6% |
| Heron Therapeutics Inc | 12 | Q4 2016 | 20.5% |
| Flamel Technologies S.A. | 12 | Q4 2016 | 6.1% |
| GW Pharmaceuticals | 11 | Q4 2015 | 19.9% |
| Lipocine Inc | 11 | Q4 2016 | 7.5% |
| Stemline Therapeutics Inc | 11 | Q4 2016 | 1.7% |
| Zafgen Inc | 10 | Q3 2016 | 5.7% |
View VHCP Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2018-02-28 |
| 13F-HR | 2017-02-13 |
| 13F-HR | 2016-11-14 |
| 13F-HR | 2016-08-12 |
| 13F-HR | 2016-05-13 |
| 13F-HR | 2016-02-12 |
| 13F-HR | 2015-11-13 |
| 13F-HR | 2015-08-13 |
| 3 | 2015-06-17 |
| 13F-HR | 2015-05-14 |
View VHCP Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.